Objectives: We evaluated ‰ow parameters measured by phase-contrast magnetic resonance (MR) imaging (PC-MRI) of the portal venous system and liver stiŠness measured by MR elastography (MRE) to determine the usefulness of these methods in predicting gastroesophageal varices (GEV) in patients with chronic liver disease (CLD).
Introduction
Gastroesophageal varices (GEV) and bleeding from them are severe complications of portal hypertension in patients with chronic liver disease (CLD). GEV develop in 7z of patients with cirrhosis each year, and occurrence of aˆrst variceal hemorrhage at one year from diagnosis is approximately 12z. 1 Mortality associated with GEV bleeding ranges from 30 to 70z. 2 Combined treatments, such as vasoactive drugs (beta-blockers), endoscopic ligation, and transjugular intrahepatic portosystemic shunt, have been developed to prevent GEV bleeding. 3, 4 Liverˆbrosis, a cause of portal hypertension, plays a fundamental role in the development of GEV, and clinicians must monitor patients with liverˆbrosis for them. Endoscopy is commonly used to identify GEV, but screening is time consuming and costly, and serious complications, though rare, can occur. Ideally, endoscopic screening for GEV would be restricted to a well targeted population of patients with cirrhosis.
Phase-contrast MR imaging (PC-MRI) has been developed in manyˆelds to measure ‰ow in the Magnetic Resonance in Medical Sciences cardiovascular system, pulmonary artery, cerebrospinal ‰uid, and portal venous system. [5] [6] [7] [8] Liver cirrhosis and portal hypertension change the hemodynamics of the portal venous system. 9 Demonstration by a previous study of altered rate of ‰ow in the portal vein (PV) in patients with GEV suggested that ‰ow in the vessel might serve as a predictor of GEV bleeding. 10 Patients with high risk of developing GEV can also be targeted by estimating degree of liverˆbro-sis using recently developed methods or a clinically useful blood biochemical index, such as aspartate aminotransferase (AST) platelet ratio index (APRI). [11] [12] [13] [14] [15] MR elastography (MRE) is a state-ofthe-art tool for evaluating liver stiŠness that oŠers high reproducibility, repeatability, and validity. [16] [17] [18] [19] [20] [21] MR examination of the liver can be shortened by performing both PC-MRI and MRE during the delay before equilibrium-or hepatocyte-phase after administration of a contrast agent. 22, 23 Use of these examinations to predict GEV would signiˆcantly enhance the utility of MR imaging in managing patients with cirrhosis.
We evaluated the utility of ‰ow parameters measured by PC-MRI of the portal venous system and liver stiŠness measured by MRE of the liver for predicting GEV in patients with CLD.
Materials and Methods

Subjects
Our institutional review board approved this retrospective study, and written informed consent was waived. March 1 through December 31 in 2011, 697 patients underwent both PC-MRI of the portal venous system (PV) and superior mesenteric vein (SMV) and MRE at our institution; 305 of the 697 had CLD. We randomly selected 60 control subjects from the patients without CLD who exhibited no liver abnormality other than hepatic cyst or hemangioma, which was conˆrmed by clinical follow-up and multi-imaging modalities. Of the 305 patients with CLD, we excluded 110 patients who met at least one of the following 5 criteria: 64 patients who did not undergo upper endoscopic examination within 6 months of MR examination; 28 with history of interventional treatment for GEV, such as endoscopic ligation and balloon-occluded retrograde transvenous obliteration;ˆve with PV thrombus conˆrmed by contrast-enhanced computed tomography; four for whom PC-MRI failed because of motion artifact; and nine with history of lobectomy or more than one segmentectomy of the liver. This yielded a study cohort of 195 patients with CLD who underwent at least one upper endoscopic examination within 6 months of PC-MRI (Fig. 1) .
CLD types included 130 cases positive for hepati- Reference standard of GEV Gastroenterologists specialized in endoscopy from our institution's Department of Digestive Medicine performed all upper endoscopic examinations, recording the presence or absence of GEV. When GEV was present, they identiˆed the form of GEV and type of red color (RC) sign, according to the general rules for recording endoscopicˆndings of esophagogastric varices (Second Edition of the Japanese Research Society for Portal Hypertension). 24 This system categorizes forms of varices as: straight and small, F1; moderately enlarged and beady, F2; markedly enlarged and nodular or tumor-shaped, F3. Results of endoscopic examinations of patients with history of GEV bleeding within 6 months of PC-MRI were designated positive for RC sign regardless of other endoscopiĉ ndings.
We divided patients into 3 groups by GEV form and RC sign on endoscopicˆndings: 85 patients with no GEV (Fig. 2a) ; 62 patients with mild GEV, with F1 and negative RC sign (Fig. 2b) ; and 48 patients with severe GEV, with either F2-F3 or positive RC sign (Fig. 2c) . We recommended endoscopic treatment in our institution for patients with severe GEV (Fig. 2c) .
PC-MRI
To avoid confounding eŠect of increased mesenteric blood ‰ow from eating, 25, 26 all subjects fasted at least 3 hours before undergoing MR imaging examination using a 1.5-tesla scanner (Signa; GE Healthcare, Milwaukee, WI, USA). For reference, we acquired images of 4-mm thick coronal slices of the portal venous system using FIESTA sequence (fast imaging employing steady-state acquisition). All patients underwent breath-hold 2-dimensional (2D) PC-MRI to measure ‰ow in the PV and SMV. Slices were set as cross-sections perpendicular to the direction of ‰ow of the PV and SMV (Fig. 3) . Imaging parameters for PC-MRI were: repetition time (TR)/echo time (TE), 12.5/5 ms; ‰ip angle, 
Visual analysis
We visually assessed routine dynamic contrastenhanced MR imaging in all patients for the presence or absence of GEV (visible GEV), deˆned as luminal dilated vessels abutting or protruding into the luminal space, 27 and visible collateral pathways of the PV, deˆned as tortuously dilated paraumbilical vein, spleno-renal shunt, and paraesophageal vein.
MR elastography
MRE was performed by attaching a cylindrical passive driver across the patient's right chest wall using an elastic (rubber) belt to deliver a pneumatic vibration to the chest wall and liver via a plastic cylinder from a generator placed outside the MR examination room. The generator of the vibration and passive driver were developed at the Mayo Clinic (Rochester, MN, USA).
We employed a breath-hold 2D gradient-echo MRE sequence to acquire axial wave images, setting the scanning position above the gallbladder and below the subphrenic region of the liver. 14 MRE imaging parameters were: (TR/TE), 100/27 ms; continuous sinusoidal vibration, 60 Hz; FOV, 30 to 34 cm×40 to 45 cm; matrix size, 256×64; ‰ip angle, 309 ; slice thickness, 10 mm; number of slices, 2; evenly spaced phase oŠsets, 4; and a single cycle of a 60-Hz trapezoidal motion-encoding gradient, with zero-andˆrst-moment nulling along the through-plane direction. We did not use parallel imaging. Total acquisition time was 64 s (four 16-s breath holds) ( Table 1 ). The MR scanner automatically generated elastograms by processing the acquired propagating shear wave images using a previously described inversion algorithm. Shear stiŠness of the tissue was determined as a pixel value (kPa).
We evaluated the ROI in the right lobe of the liver on the elastogram in the slice proximal to the center of the passive driver placed on the patient's chest wall. We did not use the left lobe for ROI measurement to avoid the eŠects of cardiac motion on the MRE phase image. Generally, we placed ROIs of 1.0 to 1.5 cm 2 near the anterior edge of the liver where the penetrating wave was well visualized and no interference was observed on the phase image. The magnitude image was also used to place the ROI in the liver region to avoid intrahepatic vessels or bile ducts. The average value in the ROI was used as an indicator of liver stiŠness by MRE.
Blood test-based hepaticˆbrosis marker
As a blood test-based marker of liverˆbrosis, we used AST platelet ratio index (APRI), calculated as 28 : APRI＝(AST level/upper limit of AST)/ (platelet counts/10 6 )×100. We consider the upper limit of AST as 32 IU/L at our institution.
Statistical analysis
We used Mann-Whitney U test to compare ‰ow-related parameters by PC-MRI between patients with CLD and control subjects and Kruskal-Wallis test to assess univariate analysis of patients' characteristics (age, sex, body weight, and Child-Pugh grade), ‰ow-related parameters, liver stiŠness by MRE, and APRI among the 3 GEV groups. We then compared theseˆndings with the proportions of visible GEV among the 3 GEV groups.
We used logistic regression to perform multivariate analyses to discriminate presence and absence of GEV and severe GEV from absent to mild GEV and included only the variables showing signiˆcant diŠerences in the univariate analysis. Before multivariate analyses, we calculated a correlation coe‹cient between the variables to assess colinearity. We performed receiver operating characteristic (ROC) analysis to estimate the e‹cacy of discrimination. We also performed subgroup analysis that excluded patients with collateral pathways. All statistical analyses were performed using JMP version 9 software (SAS Institute Japan, Tokyo, Japan). Data are presented as mean±standard deviation.
Results
Comparison of parameters by PC-MRI between patients with and without CLD
We observed statistically signiˆcant diŠerences in V PV , V SMV , S PV , S SMV and Q SMV between patients with CLD and control subjects ( Table 2) .
Comparison of parameters by PC-MRI and liver stiŠness by MRE in patients with CLD
We observed statistically signiˆcant diŠerences in Child-Pugh class, V PV , S PV , liver stiŠness, APRI, and distribution of visible GEV among the GEV groups (Table 3) .
Multivariate analysis for discriminating presence or absence of GEV None of the parameters showing signiˆcant diŠerences in the univariate analyses (Child-Pugh grade, V PV , S PV , liver stiŠness, APRI, and visible GEV) showed a square of correlation coe‹cient greater than 0.5; therefore, we included all these parameters in our multivariate analyses.
Multivariate regression analysis identiˆed V PV , S PV , liver stiŠness, and visible GEV as independent indicators for discriminating absence, presence, and degree of GEV (Table 4 ). The area under the ROC curve (AUC) was 0.70 for V PV , 0.64 for S PV , and 0.69 for liver stiŠness. Visible GEV showed 14z sensitivity and 98z speciˆcity. In a subgroup analysis that excluded 32 patients with collateral pathways, the diagnostic performances of V PV and liver stiŠness were slightly improved (Table 5) ; the AUC was 0.73 for V PV and 0.71 for liver stiŠness.
Multivariate analysis for discriminating severe from absent to mild GEV Multivariate analysis demonstrated V PV , S PV , and visible GEV, but not liver stiŠness, as independent indicators for discriminating severe from absent to mild GEV ( Table 4 ). The AUC was 0.72 for V PV and 0.64 for S PV . Visible GEV showed 30z sensitivity and 98z speciˆcity. In the subgroup analysis, the diagnostic performances of V PV and S PV did not change (Table 5 ). Figure 4 shows MR elastograms, liver stiŠness, and V PV of representative cases from the 3 GEV groups (Fig. 4a , absent GEV; 4b, mild GEV; 4c, severe GEV).
Discussion
In this study, we sought to develop a noninvasive predictor of GEV using functional MR imaging. Some reports have suggested that PV ‰ow volume calculated by PC-MRI or by Doppler ultrasound is not a useful predictor of advanced GEV, 27, 29 and our data conˆrmed this. PV ‰ow volume did not diŠer signiˆcantly between patients with CLD and controls. S PV increased in proportion to the portal pressure in patients with GEV. As a result, measuring V PV is more reliable than calculating PV ‰ow volume for predicting GEV or portal hypertension, as shown in our analysis. We also demonstrated liver stiŠness measured by MRE as a signiˆcant indicator for discriminating patients with and without GEV. However, though liver stiŠness and APRI are valid markers of hepaticˆbrosis, they were not useful predictors of clinically important or severe GEV. These results suggest that hepatiĉ brosis develops before portal pressure increases.
In the subgroup analysis that excluded patients with collateral pathways of the portal venous system, the diagnostic performance of V PV and liver stiŠness were slightly improved. This result suggests that confounding factors of collateral pathway development negatively aŠect the diagnostic performance of these functional parameters.
Visibility of GEV on routine dynamic contrastenhanced MR imaging showed high speciˆcity (98z) and low sensitivity (14 to 30z) for predicting presence of GEV in this study; on routine MR imaging, only advanced dilated GEV was visibly identiˆable. One previous report demonstrated moderate sensitivity (60-90z) and excellent specicity (70-100z) of computed tomography (CT) and MR imaging for detecting varices. 30 The diŠer-ent diagnostic criteria for varices of the previous 
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report and ours may account for this discrepancy in sensitivity. Another more accurate morphological assessment of the portal venous system, such as 3D contrast-enhanced MR portography, 31 is also reported. However, we believe functional quantitative parameters may be more subjective than qualitative morphological assessment. Previous Doppler ultrasound-based studies have found no signiˆcant diŠerence in V PV among variceal grades (e.g., small vs. large varices or F1 vs. F2 vs. F3 varices). 29, 32 We speculate this discrepant nding is due to the diŠerent precision of the 2 measurement modalities. Doppler ultrasound can measure ‰ow in the PV and may be cheaper and more widely available than PC-MRI. However, ‰ow measurement is more valid by PC-MRI than ultrasonography, which yields more variable and overestimated results. 33 The decreased V PV in patients with GEV is thought to result from the constant rather than pulsatile ‰ow of the venous system because the pressure gradient between the PV and the sinusoids of the liver is considered a driving force of PV ‰ow. If sinusoidal pressure increases as hepaticˆbrosis develops, the pressure gradient and V PV will decrease. Thus, we propose a decrease in V PV as a direct indicator of portal hypertension. Evaluating chronic pulmonary arterial hypertension (PAH) using breath-hold 2D cine PC-MRI applied to the pulmonary artery, Sanz and colleagues showed average pulmonary artery velocity to be the most useful parameter in predicting chronic PAH. 8 We speculate that a similar relationship exists between portal hypertension and V PV .
Our study has some limitations. First, we did not assess the predictability of GEV bleeding, the most important clinical outcome. Further longitudinal evaluation is warranted; we hope functional MR imaging parameters may be more useful than morphological assessments in predicting future GEV bleeding and clinical prognosis in patients with CLD. Second, it seemed we could eliminate the confounding eŠects of increased mesenteric venous ‰ow from eating by having patients fast for at least 3 hours; the robustness of PV ‰ow measurement on only one slice at a speciˆc time point should be considered. Recently developed time-resolved 3-or 4-dimensional PC-MRI may soon resolve this problem. [34] [35] [36] The retrospective design also limited our study. We expect a prospective study with longitudinal observations would strengthen the conclusions of our study.
In conclusion, PV ‰ow parameters measured by PC-MRI of the portal venous system and liver stiŠ-ness measured by MRE can be useful for identifying GEV in patients with CLD.
